Certain factors may increase the likelihood of experiencing bloating on GLP-1 therapy, including: Pre-existing gastrointestinal conditions such as irritable bowel syndrome (IBS), functional dyspepsia, or small intestinal bacterial overgrowth (SIBO) Rapid dose escalation without adequate titration periods Dietary factors , particularly high intake of fermentable carbohydrates (FODMAPs), fatty foods, or carbonated beverages Concurrent medications that affect gastrointestinal motility Patients should be aware that GLP-1 receptor agonists have been associated with more serious gastrointestinal adverse effects, including pancreatitis (inflammation of the pancreas) and gallbladder disease
30 The expression of GLP-1 receptors in the human testis suggests that GLP-1 may exert direct influences on spermatogenic processes
D.: Prostate cancer chemoprevention, an overview of United States trials
Both medications contain the same active ingredient, semaglutide
GLP-1 medications delay gastric emptying through multiple mechanisms
The financial argument for quality sourcing extends beyond the immediate purchase
)
)
